Luigi Mangione expected to plead guilty to federal charges in UnitedHealthcare CEO killing

Luigi Mangione, the 28-year-old charged with killing UnitedHealthcare CEO Brian Thompson in Manhattan in December 2024, is expected to plead guilty to federal stalking charges Friday, a move that could block New York State from ever trying him for murder.

Sources familiar with the matter told NBC News that Mangione plans to enter the plea at an 11:00 a.m. hearing in Manhattan federal court. He faces two counts of stalking resulting in death, according to the U.S. Department of Justice. It remains unclear whether he will plead guilty to one or both charges.

No formal plea deal is in place. A senior DOJ source told Fox News that Mangione was expected to plead guilty without a negotiated agreement, leaving his sentence entirely in the hands of U.S. District Judge Margaret Garnett. Even with a guilty plea, the maximum federal sentence remains life without parole.

Mangione had previously pleaded not guilty to both state and federal charges. He met with his lawyers Thursday morning at the Metropolitan Detention Center in Manhattan, NBC New York reported, citing a source familiar with the matter. Earlier in the week, federal prosecutors and Mangione's defense attorneys jointly requested a last-minute conference, a move legal observers said had few explanations beyond plea negotiations.

A calculated gamble on federal prison and double jeopardy

The strategy behind the expected plea is straightforward, if risky. Mangione's defense team appears to be betting that a federal guilty plea will trigger New York's double jeopardy protections and eliminate the separate state murder case entirely. A state trial had been scheduled for September 8, with Mangione facing charges of second-degree murder, criminal possession of a forged instrument, and criminal possession of a weapon.

Paul Mauro, a retired NYPD inspector and Fox News contributor, laid out the logic plainly:

"First of all, he gets to serve his time in federal prison, where conditions are better, and he is hoping that the New York state double jeopardy law will knock out the state case now and all he ever has is the federal case."

Michael Bachner, a defense attorney and former Manhattan prosecutor speaking to ABC 7 New York as a legal observer, echoed that assessment:

"Once the feds resolve the case, the New York State constitution may say, 'you can no longer try him.'"

In other words, Mangione's team is attempting to trade one prosecution for two. Federal prison conditions are generally considered more tolerable than state facilities, and eliminating the state murder charge, which carries its own severe penalties, would simplify Mangione's legal exposure considerably.

But the gamble carries real downside. Judge Garnett holds sole discretion over sentencing. Bachner noted that in federal court, defendants cannot negotiate their sentence with the judge. "You just take a plea in federal court. Your sentence is decided by the judge on the day of sentencing," he told ABC 7. Mangione could plead guilty and still receive life without parole, the same maximum he faced at trial.

Mangione himself framed the double jeopardy argument months ago

The double jeopardy strategy did not emerge from nowhere. AP News reported that Mangione raised the issue directly with a judge back in February, saying: "It's the same trial twice. One plus one is two. Double jeopardy by any commonsense definition."

Whether New York courts would agree with that commonsense framing is an open question. The state has its own double jeopardy provisions, and Mangione's lawyers are expected to invoke them to seek dismissal of some or all state charges if the federal plea goes through. But state prosecutors have given no public indication they intend to walk away quietly.

Assistant District Attorney Joel Seidemann signaled the prosecution's posture in remarks reported by the New York Post:

"Any guilty pleas in these matters must account for the seriousness of defendant's offenses, the loss of an innocent life, the impact of those crimes on the victim's family."

That statement suggests prosecutors on both the state and federal side view the killing of Brian Thompson as a case that demands severe consequences, plea deal or not.

Judge Garnett already narrowed the federal case in January

The federal prosecution has already been trimmed. In January, Judge Garnett dismissed two counts of the federal indictment, eliminating the possibility of capital punishment. That ruling left only the two stalking-related charges on the table. The specific grounds for the dismissal were not detailed in available reporting.

With the death penalty off the table, Mangione's calculus shifted. A guilty plea to stalking charges, even ones carrying a life sentence, removes the uncertainty of a federal trial and positions his defense to challenge the state case on constitutional grounds. The Just The News report noted that if the federal plea goes through, Mangione's lawyers planned to seek dismissal of some or all state charges.

Donna Rotunno, a Chicago criminal defense attorney and Fox News contributor, suggested the strategy has some basis in sentencing reality. "Rarely somebody with no background, who's educated, gets the maximum sentences," she said, implying that Mangione, described as an Ivy League graduate with no prior criminal record, might receive less than life.

That is a bet, not a guarantee. And it rests entirely on Judge Garnett's judgment.

Key evidence includes a 3D-printed pistol and a notebook

The case against Mangione is built on physical evidence that would have been difficult to contest at trial. AP News reported that key evidence included a 3D-printed pistol matching the weapon used to kill Thompson and a notebook in which Mangione described his intent to kill an insurance executive. Those details help explain why the defense may have concluded that a trial, in either federal or state court, posed unacceptable risk.

Brian Thompson, UnitedHealthcare's CEO, was killed in Manhattan on December 4, 2024. The killing drew intense national attention, and Mangione became a polarizing figure, celebrated in some corners of the internet by critics of the health insurance industry, even as prosecutors built a case centered on premeditated violence. In a legal landscape that has seen federal prosecutors pursue charges in cases once thought untouchable, the Mangione prosecution moved with unusual speed and public scrutiny.

Plea negotiations first surfaced in June but produced no deal at the time. The sudden reemergence of talks this week, marked by the joint conference request on Tuesday and Mangione's Thursday morning meeting with his lawyers, suggests both sides saw reason to move before the September state trial date.

Nothing is final. Sources stressed that Mangione could reverse his decision at any point, even after the hearing begins Friday morning. Plea hearings in federal court require the defendant to affirm his guilt before a judge, and any hesitation or reversal would send the case back to its pre-plea posture.

A state murder trial hangs in the balance

If Mangione does plead guilty Friday, the most consequential fight may shift from the courtroom where the plea is entered to the courtroom where the state murder case sits. The second-degree murder charge, the weapons charge, and the forged-instrument charge were all set for trial in early September. A successful double jeopardy challenge would wipe those off the board.

For the family of Brian Thompson, the distinction matters. A federal stalking conviction, even one carrying a life sentence, is not a murder conviction. The state case was the vehicle for holding Mangione accountable under the specific charge of murder. If double jeopardy eliminates that path, the public record will reflect a guilty plea to stalking, not to the killing itself, at least not in the terms most people understand.

The case arrives at a moment when high-profile federal criminal proceedings continue to test public confidence in the justice system's ability to deliver proportionate accountability. And in a broader legal environment where serious federal charges against public figures command sustained national attention, the Mangione plea will be scrutinized for what it says about the gap between legal strategy and justice.

A man was shot and killed on a Manhattan sidewalk. If the system lets the accused plead to a lesser framing of that act and walk away from a murder trial, the victim's family, and the public, deserve to know exactly what was traded, and why.